StockWatch
·
Q2 FY-2027 RESULTS · BHAGERIA

Bhageria Industries Q2 FY27: consol. PAT +386% YoY to ₹55.7 Cr, margins expand sharply

PAT +385.94% YoY · revenue +122.97% · margins expanding

Q2 FY27 resultsBHAGERIABhageria Industries Ltd28 Oct 2026 · 3 min read
Revenue

₹455.7 Cr

+122.97% YoY

PAT (consolidated)

₹55.75 Cr

+385.94% YoY

Net margin

12.13%

+6.6pp YoY

EPS

₹12.81

Bhageria Industries' consolidated revenue for Q2 FY27 came in at ₹455.7 Cr, up 122.97% YoY from ₹204.4 Cr and 59.11% QoQ from ₹286.4 Cr, with consolidated PAT (profit for the period) of ₹55.75 Cr against ₹11.47 Cr a year ago (+385.94% YoY) and ₹33.91 Cr last quarter (+64.39% QoQ). EPS was ₹12.81 versus ₹2.70 YoY. Standalone PAT of ₹58.29 Cr runs about 4.4% ahead of the consolidated figure — the Group's six subsidiaries (two solar-power entities, a pharma JV, a rare-earth minerals unit and others) posted a combined net loss of ₹2.11 Cr for the quarter per the auditor's review report, pulling the consolidated print below standalone.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹455.7 Cr+59.1%+123%
Expenses₹384.05 Cr+50.1%+102.2%
PAT₹55.75 Cr+64.39%+385.94%
Net margin12.13%+0.9pp+6.6pp
EPS₹12.81+63.6%+374.4%

The growth is driven almost entirely by the Chemicals segment: standalone segment revenue nearly doubled YoY to ₹446.68 Cr from ₹197.47 Cr, and segment profit (PBIT) more than quadrupled to ₹80.37 Cr from ₹19.78 Cr. That flowed straight through to margins — consolidated NPM expanded to 12.13% from 5.57% YoY (11.23% last quarter), and OPM (EBITDA/revenue) rose to roughly 18.58% from 11.30% YoY (14.68% last quarter), indicating strong operating leverage from a chemicals price/volume recovery rather than a one-off gain. Neither statement carries an exceptional item, so the growth reads as organic.

₹
176.3239.59302.88366.16429.45333.4507-2708-1809-0910-0510-28Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹333.45, down 15.3% over the past month of trading.

₹ Cr
020.8141.6362.4410.88Q1 FY26rev ₹157 Cr11.47Q2 FY26rev ₹204 Cr10.84Q3 FY26rev ₹242 Cr11.3Q4 FY26rev ₹271 Cr33.91Q1 FY27rev ₹286 Cr55.75Q2 FY27rev ₹456 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

There is no usable street benchmark for this print: TipRanks lists only one tracking analyst with no revenue or EPS estimates filed, so vsStreet is unknown, and the company has issued no formal guidance in our records, so vsGuidance is also unknown; no management press release was available to cross-check framing. Among the quarter's disclosed developments, the one unrelated to operating performance is the ongoing SEBI order challenge, which SAT adjourned to January 5, 2027 — a governance overhang that doesn't show up in these numbers but remains unresolved.

  • W1

    Sustainability of chemicals segment OPM (~18.58% this quarter vs 11.30% a year ago) into Q3 FY27, with no formal guidance on record

  • W2

    NCI drag from loss-making subsidiaries (₹2.11 Cr quarterly, ₹3.59 Cr H1 combined loss) — whether solar/pharma/rare-earth units narrow losses as they scale

  • W3

    Outcome of the SEBI order challenge at SAT, adjourned to Jan 5, 2027

Converted from ₹ Lakhs. Standalone tax sub-lines (current/deferred/earlier-years) print but don't additively reconcile to PBT-PAT; used total tax = PBT-PAT (equals the 'Current tax' row in every column, consistent across all 6 periods). Consolidated PAT uses 'Profit for the period' (total, ₹55.75 Cr), matching our DB's historical methodology exactly for prior quarters; owners'-share profit was ₹55.92 Cr (NCI loss ₹0.18 Cr) due to 6 loss-making subsidiaries.

Informational and educational content only. Not investment advice.